{"filing":{"accession_number":"0001193125-26-345807","cik":"0001540171","ticker":"AVLN","company_name":"Avalyn Pharma Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ck0001540171-20260812.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540171/000119312526345807/ck0001540171-20260812.htm"},"events":[{"id":27061,"run_id":24632,"accession_number":"0001193125-26-345807","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release disclosing Avalyn Pharma's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($24.7M), G\u0026A expenses ($6.6M), net loss ($28.9M), and cash position ($413.5M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and balance sheet data, which are typical of quarterly earnings announcements. Material to investors assessing the company's financial condition and cash runway.","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28428,"accession_number":"0001193125-26-345807","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Avalyn Pharma's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($24.7M), G\u0026A expenses ($6.6M), net loss ($28.9M), and cash position ($413.5M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and balance sheet data, which are typical of quarterly earnings announcements. Material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:07:41.727261+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28428,"accession_number":"0001193125-26-345807","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Avalyn Pharma's financial results for Q2 2026 (ended June 30, 2026), including R\u0026D expenses ($24.7M), G\u0026A expenses ($6.6M), net loss ($28.9M), and cash position ($413.5M). The press release is furnished as Exhibit 99.1 and includes condensed consolidated financial statements and balance sheet data, which are typical of quarterly earnings announcements. Material to investors assessing the company's financial condition and cash runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:07:41.727261+00:00","company_name":"Avalyn Pharma Inc.","ticker":"AVLN","filing_date":"2026-08-12"}]}